Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284322 · ClinicalTrials.gov registry record · Phase 1
Fresolimumab In Systemic Sclerosis
A Phase 1 study of Diffuse Systemic Sclerosis, sponsored by Boston University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01284322 is a Phase 1 study of Diffuse Systemic Sclerosis that has completed, run by Boston University. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01284322, a Phase 1 study of Diffuse Systemic Sclerosis, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
Conditions Studied
Interventions
- DRUG Fresolimumab
Study Locations (1)
Massachusetts
- Boston University School of Medicine; Rheumatology/Arthritis Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284322
The ClinicalTrials.gov registry entry for NCT01284322 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diffuse Systemic Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Fresolimumab is the first listed.
NCT01284322 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01284322 about?
NCT01284322 is a clinical study titled "Fresolimumab In Systemic Sclerosis". The purpose of this study is to determine if fresolimumab is safe in treating people with systemic sclerosis (scleroderma) and to investigate the effect of fresolimumab in the skin of these individuals.
What is the current status of trial NCT01284322?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-01. Estimated completion is 2014-03.
What conditions does trial NCT01284322 study?
This clinical trial studies the following conditions: Diffuse Systemic Sclerosis.
What interventions are being tested in trial NCT01284322?
The interventions under investigation include: Fresolimumab (DRUG).
Who is sponsoring clinical trial NCT01284322?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01284322 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.